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compared to calcitonin and alendronate. Furthermore,
hazard ratios showed that patients taking ERT, ralox-
ifene, or alendronate were approximately 83% less likely
to experience fracture at any point in time compared to
calcitonin.
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BACKGROUND: The UK has more than 19 million peo-
ple aged over 50, including about 9.4 million aged over
65. Demographic changes will lead to increases in the
over-50 population of 10% and 25% by 2010 and 2020,
respectively. There are already 3 million UK residents
with osteoporosis, but the prevalence of osteoporosis in-
creases with age, and the public health impact of os-
teoporosis will increase substantially over the next 20
years. OBJECTIVE: To predict fracture numbers and
corresponding costs for men and women aged 50–99
years in the UK for the years 2000 to 2020. METHODS:
A Markov model was designed to simulate the natural
history of osteoporosis within the UK population. Inputs
to the model included age/sex specific fracture incidence
rates, published unit costs for different fracture types
(hip, vertebral, forearm/wrist, other), age/sex specific
mortality rates, and age/sex specific population totals.
Total fracture numbers were adjusted using published
site-specific attribution figures to identify the number
that were a consequence of osteoporosis. Iteration tech-
niques were employed across ages 50–99 in men and
women, to generate the distribution of prevalence-based
estimates of fractures and costs for the base year 2000.
Osteoporosis costs and fracture numbers were then pro-
jected into future years by applying growth rates in age/
sex specific population totals to these year 2000 esti-
mates. RESULTS: In 2000 there were 190,000 os-
teoporosis-related fractures at a cost of £1.8 billion. Men
accounted for 32,000 fractures and £330 million. By
2020, annual osteoporotic fracture numbers increased by
over 21% to 230,000, with costs growing by 20% to
over £2.1 billion. Cumulative totals for 2000–2010 were
2.2 million fractures and £20.3 billion. CONCLUSIONS:
Osteoporotic fractures will have substantial and increas-
ing impacts on UK health services unless highly effective
preventative interventions achieve widespread use.
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OBJECTIVE: While Cox 2 inhibitors have a theoretical
advantage over other nonsteroidal anti-inflammatory
drugs (NSAIDS) by reducing gastrointestinal (GI) side ef-
fects, not all individuals are at increased risk of GI com-
plications and therefore may benefit equally from non-
Cox 2 specific NSAIDS. This study determined the use of
Cox 2 inhibitors by subjects with no identifiable GI risk.
The cost of this “inappropriate use” was estimated.
METHODS: This was a longitudinal claims data analysis
using 1999 medical, pharmacy and enrollment data from
a large national health plan. Subjects were identified as
either Cox 2 users (n  23,190) or other NSAID users
(n  192,079) from pharmacy claims, and total NSAID
costs were calculated for a six-month period. RESULTS:
Cox 2 users were more likely to have a GI risk factor,
(prior GI events, age over 60 years, chronic NSAID use of
two or more prescriptions in the six months prior to the
first Cox 2 claim, and prior corticosteroid use) compared
to other NSAID users. Because individuals with arthritis
may require on-going NSAID use, a diagnosis of arthritis
(OA or RA) was also considered a risk factor for GI com-
plications. Having an arthritis diagnosis was more likely
among Cox 2 users compared to other NSAID users
(44.1% and 13.0% respectively). Twenty-six percent of
Cox 2 users had neither a discernable GI risk nor an ar-
thritis diagnosis. An unadjusted cost comparison between
Cox 2 subjects with no GI risk and no arthritis and simi-
lar other NSAID subjects found a significant mean differ-
ence of $131 per person in NSAID costs for six months.
CONCLUSIONS: Despite health plan policies to manage
the use of Cox 2 inhibitors, a quarter of Cox 2 users ap-
peared to be inappropriate. The total health system cost
of this potentially inappropriate use was $775,000 for six
months.
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OBJECTIVES: Quality of life is a key parameter in de-
scribing the health status patients of rheumatoid arthritis.
Construct validity of a generic (EQ-5D) and a disease
specific (RAQoL) quality of life instrument was tested
with the intention of further use in clinical and health
economic trials and burden of disease studies in Hun-
gary. METHODS: RAQoL and EQ-5D have been re-
cently adapted into Hungarian. Authors analysed the de-
mographic and QoL data from a cross-sectional postal
survey of patient with rheumatoid arthritis. The conver-
gent validity of EQ-5D, RAQoL scores has been com-
pared to functional measurement scores from the Health
Assessment Questioner (HAQ). Pearson correlation coef-
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ficients were used to assess the level of association. RE-
SULTS: 81 patients participated in the study. Mean age
of the sample was 57.3 (SD  10.1) years, 89% (n  72)
were female. The average disease duration among pa-
tients was 14.5 (SD  10.6) years. RAQoL scores were
relatively strongly correlated (Pearson coefficient  0.662)
with HAQ scores. The EQ-5D index scores showed higher
correlation (0.627) with HAQ than the Visual Analogue
Scale of EQ-5D (0.463). The Pearson Correlation Coeffi-
cient between RAQoL and EQ-5D index scores was
0.515, and between RAQoL and EQ-5D VAS scores was
0.396. CONCLUSIONS: Results suggest that the Hun-
garian RAQoL is a valid instrument of measuring QoL of
rheumatoid arthritis patients. The EQ-5D index provides
also appropriate results, and can be proposed for cost-
utility analyses. However EQ-5D VAS scores are not rec-
ommended to describe the QoL of patients with rheuma-
toid arthritis.
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OBJECTIVES: The purpose of this study is to examine
the cost-effectiveness (CE) of rofecoxib versus NSAIDs in
the treatment of osteoarthritis. METHODS: The authors
used decision-analysis from a societal perspective to
model a hypothetical cohort of osteoarthritis patients on
long-term NSAID therapy. Incremental cost per QALY
(C/QALY) estimates were calculated for a hypothetical
trial population and for patients at high risk of G.I. ad-
verse events. High-risk patients were defined in the litera-
ture as having four risk factors combined: history of G.I.
bleeds, history of peptic ulcer, cardiovascular disease and
age 75 years or greater. All costs were expressed in 1997
prices. Utility estimates were obtained from a separate
analysis of pharmacy claims data including the Health
Utilities Index Mark 2 from a large HMO. Confidence
intervals were assessed using the maximum and mini-
mum values from the literature. Univariate sensitivity and
threshold analysis were conducted. RESULTS: The C/
QALY range is $5,658 to $108,831 for osteoarthritis pa-
tients; base case C/QALY is $103,597 for all osteoarthri-
tis patients, $9,374 for high-risk patients. Rofecoxib is
cost-effective (C/QALY $50,000) if the incidence of
perforations, ulcers and bleeds (PUB) is 0.098 per year or
greater. Sensitivity: the most sensitive parameters were:
symptomatic dyspepsia utility; rofecoxib price; symptom-
atic peptic ulcer utility; incidence of G.I. symptoms;
NSAID price and incidence of PUBs. However, the pa-
rameters with greatest uncertainty and variability in the
literature are incidence of PUBs and G.I. symptoms.
CONCLUSION: The point estimate C/QALY of rofe-
coxib for all osteoarthritis patients varies from very cost-
effective to not cost-effective depending on assumptions
for the probability of PUBs and G.I. symptoms. Rofe-
coxib is cost saving for patients at high risk of developing
G.I. complications.
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OBJECTIVE: To evaluate the correlation between gen-
eral measures of function and well-being, as measured by
the 8 domains of the SF-36, with arthritis specific mea-
sures of function and symptom frequency. METHODS:
We identified 606 patients from a longitudinal, observa-
tional study of RA (RAPOLO). Patients completed tele-
phone interviews about arthritis specific function (HAQ,
RA Status and Symptoms), the SF-36 domains, Physical
and Mental Summary Scores (PCS, MCS) and the Arthri-
tis Specific Health Index (ASHI). We present correlations
between the SF-36 domains, PCS, MCS and ASHI with
selected arthritis measures. All correlations are presented
as absolute values. RESULTS: All correlations were in
the anticipated direction. A correlation 0.6  good–ex-
cellent, and 0.4  below average. The HAQ was highly
correlated with the SF-36 physical scales, and had weak
correlations with the emotional function scales and the
ASHI. Other arthritis specific scales (joint swelling, joint
pain, morning stiffness, RA fatigue and RA pain) were
strongly correlated with the ASHI, the SF-36 pain, physi-
cal function, role function-physical and energy/fatigue
scales; and had weak correlations with the emotional
functioning and general health scales. CONCLUSIONS:
In RA patients, the SF-36 measures aspects of functioning
and well-being not covered by the arthritis specific mea-
sures, especially in the areas of emotional functioning.
This is indicated by the moderate to weak correlations
between the arthritis specific measures and the domains
of emotional function, role emotional function, and men-
tal health and the MCS.
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OBJECTIVE: To compare osteoporosis treatment charges
among patients treated with an estrogen versus a selective
estrogen receptor modulator (SERM) in a managed care
population. METHODS: Patients 40 years of age with a
